News

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007

(Corticosteroid for inflammation and pain after cataract surgery) TAIPEI – June 3, 2021 – Formosa Pharmaceuticals (“Formosa”, stock code:6838), a subsidiary of Formosa Laboratories (TWSE stock code:4746), and China Grand Pharma (“Grand”, HKG stock code:00512) announce that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the …

Formosa Pharmaceuticals and China Grand Pharmaceutical and Healthcare Holdings Limited enter into licensing agreement for APP13007 Read More »

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital

April 16, 2021 Formosa Pharmaceuticals (FP), a subsidiary of Formosa Laboratories (TWSE 4746), has successfully completed a Series C financing round, increasing its cash capital by NTD $600 million (approx. USD $21.1 million). In addition to the continuous support from major shareholder, Formosa Laboratories, numerous prominent venture capital firms participated in this round of capital …

Formosa Pharmaceuticals completes USD $21.1 million fundraising and increase in cash capital Read More »

APP13007 completes Phase 2 clinical trial and EOP2 meeting.

Formosa Pharmaceuticals and AimMax Therapeutics report top-line results from a Phase 2 clinical trial of APP13007 for the treatment of inflammation and pain after cataract surgery. The End-of-Phase 2 meeting with the FDA is successful, setting the stage for pivotal Phase 3 trials to begin as early as 2020-Q4. APP13007 meets primary endpoints demonstrating rapid …

APP13007 completes Phase 2 clinical trial and EOP2 meeting. Read More »

Scroll to Top